Author

Jeffrey R. Haworth

Institution: Akston Biosciences (United States)

Observed institution: Akston Biosciences (United States)

ORCID: 0000-0002-2880-0363

Observed ORCID: 0000-0002-2880-0363

OpenAlex ID: A5066485853

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

2021 · David G. Alleva, Andrea R. Delpero, et al. · Vaccine · 39

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

2023 · Eline A. Feitsma, Yester F. Janssen, et al. · Vaccine · 16

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

2022 · Yester F. Janssen, Eline A. Feitsma, et al. · Vaccine · 16

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

2024 · David G. Alleva, Eline A. Feitsma, et al. · npj Vaccines · 2

Works count: 4

Citation count: 73

H-index: 3

I10-index: 3